Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT04356742

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04356742
Other papers using this trial's data
  • Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study Diabetes, obesity & metabolism, 2024-11 DOI, PubMed 39223856

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04356742. Randomized; triple masking; primary purpose treatment. Start 2020-05-26 (actual); primary completion 2022-02-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Intervention (Drug)
Dapagliflozin 10mg
Intervention (Drug)
Placebo
Intervention (Drug)
Evogliptin 5mg
Intervention (Drug)
Metformin≥1000mg
Lead sponsor
Dong-A ST Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04356742
Content hash
474c6772aa9f0e8f4d836da754760063ff5b05610aa27d6c1a3ffddebf45c2e5